Rapid HCV diagnostics: aligning molecular innovation with real-world elimination needs

Area of Science:

• Molecular diagnostics
• Virology
• Point-of-care testing

Background:

• Hepatitis C virus (HCV) diagnosis is crucial for treatment and elimination efforts.
• Decentralised care models require rapid and accessible diagnostic tools.
• The DASH platform offers potential for automated molecular assays.

Purpose of the Study:

• To comment on the development of a rapid, automated point-of-care PCR assay for HCV RNA by Reed et al.
• To discuss translational considerations for the real-world implementation of this diagnostic assay.
• To highlight the importance of aligning diagnostic innovation with global HCV elimination goals.

Main Methods:

• Commentary on a published study describing a novel diagnostic assay.
• Discussion of translational factors including cost, infrastructure, workflow, and validation.
• Analysis of analytical sensitivity in relation to programmatic requirements.

Main Results:

• The described assay represents a significant advancement in accelerating molecular diagnosis for HCV.
• Key considerations for implementation include cost-effectiveness, operational simplicity, and clinical validation.
• Alignment between assay sensitivity and public health needs is critical.

Conclusions:

• The rapid, automated point-of-care PCR assay for HCV RNA on the DASH platform is a promising development.
• Successful real-world implementation hinges on addressing practical challenges like cost and workflow.
• Continued innovation focused on affordability and scalability is essential for global HCV elimination.